The research, led by Min Min, Jun Zhang, Jingjing Wang, Yin Chen, and Hewei Luan of the Department of Laboratory Medicine at Jurong Hospital, Jiangsu University, in Zhenjiang, China, set out to clarify what LAIR1 actually does in CLL. LAIR1 is an inhibitory receptor expressed on the surface of many immune cells, including natural killer cells, T cells, B cells, and myeloid lineages. Its cytoplasmic tail carries immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which, upon ligand binding, recruit phosphatases that blunt cellular activation signals. In the context of cancer, inhibitory receptors have typically been viewed through the lens of immune evasion, as tumors can exploit such pathways to escape immune surveillance. The new findings, however, suggest that in CLL the story may be more nuanced, with LAIR1 expression levels correlating with disease outcome in a way that hints at a protective role.

To dissect the cellular landscape of CLL, the team began with single-cell RNA sequencing analysis, a technique that allows researchers to profile gene expression in individual cells rather than in bulk tissue samples. Using uniform manifold approximation and projection (UMAP) for dimensionality reduction and principal component analysis to characterize transcriptional variation, they mapped the cellular signatures within CLL samples and identified the key cell populations populating the leukemic microenvironment. Among these, macrophages emerged as a particularly important population, exhibiting the highest expression of LAIR1 of any cell type examined. This observation is notable because tumor-associated macrophages are increasingly recognized as central architects of the tumor microenvironment in many malignancies, shaping immune responses, supporting tissue remodeling, and influencing treatment response.

With the cellular context established, the investigators turned to comparative expression analysis. Drawing on public datasets, including resources from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA), they compared LAIR1 expression between CLL samples and healthy control samples. The results were consistent across bioinformatic and experimental approaches: LAIR1 expression was significantly decreased in CLL compared with controls. This downregulation raised an immediate clinical question. If LAIR1 is lost as the disease develops, does the degree of loss carry prognostic weight? To answer this, the team stratified CLL patients into two groups according to the optimal cutoff value of LAIR1 expression and compared their survival outcomes using Kaplan-Meier analysis.

The survival analysis delivered a striking result. Patients in the low LAIR1 expression group had significantly worse prognosis than those whose tumors retained higher levels of the receptor. In other words, the more LAIR1 expression was diminished, the poorer the clinical outlook. This kind of expression-outcome relationship does not by itself prove causation, but it provides a compelling correlation that justified the next phase of the study: directly testing what LAIR1 does to leukemic cells when its expression is experimentally restored. Correlative findings in cancer genomics frequently dissolve under functional scrutiny, so the team designed a series of laboratory experiments to move from association toward mechanism.

The functional work centered on a human CLL cell line. The researchers constructed LAIR1 overexpression variants of these cells and confirmed that the receptor was genuinely upregulated at both the messenger RNA and protein levels, using real-time quantitative polymerase chain reaction (RT-qPCR) and Western blotting respectively. RT-qPCR amplifies complementary DNA copies of specific transcripts to quantify gene expression with high sensitivity, while Western blotting uses antibody-based detection to measure protein abundance, and agreement between the two methods gave the team confidence that their engineered cell lines faithfully reflected LAIR1 overexpression. With the model system validated, they proceeded to the central question: what happens to CLL cells when LAIR1 is abundantly present?

The answer came from flow cytometry, a technique that passes thousands of individual cells in rapid succession through laser beams, allowing researchers to quantify fluorescent signals attached to specific cellular features. By staining cells with propidium iodide (PI), a dye whose uptake reflects DNA content, the team could determine the distribution of cells across the phases of the cell cycle. By applying annexin-based apoptosis assays, they could measure the fraction of cells undergoing programmed cell death. The results were clear and internally consistent. CLL cells engineered to overexpress LAIR1 displayed a shortened S phase, the portion of the cell cycle devoted to DNA replication, and exhibited significantly increased rates of apoptosis. In effect, restoring LAIR1 pushed the leukemic cells away from proliferation and toward self-destruction.

These findings carry conceptual weight because they link an immune inhibitory receptor to the core proliferative machinery of the cancer cell itself. A shortened S phase combined with elevated apoptosis suggests that LAIR1 overexpression disrupts the carefully balanced cell cycle regulation that allows CLL cells to accumulate slowly over years. CLL is notorious for its dependence on anti-apoptotic signaling, particularly through the BCL-2 family of proteins, which is precisely why BCL-2 inhibitors such as venetoclax have proven so effective in the clinic. The observation that LAIR1 overexpression increases apoptotic rates places the receptor on the same functional axis as the pathways that current drugs target, albeit from a different molecular entry point. Whether LAIR1 acts directly on cell cycle regulators or indirectly through downstream signaling from its ITIM motifs remains an open question that the study does not fully resolve, but the phenotypic effect is unambiguous in the experimental system used.

The macrophage connection adds a further layer of biological interest. The single-cell analysis identified macrophages as the highest LAIR1-expressing cells in the CLL microenvironment, which raises the possibility that the receptor’s influence on disease progression is mediated, at least in part, through the tumor microenvironment rather than through the malignant B cells alone. Tumor-associated macrophages can adopt polarized states that either support or suppress tumor growth, and inhibitory receptors like LAIR1 are key regulators of macrophage activation. A scenario in which reduced LAIR1 expression licenses macrophages toward a more tumor-permissive state, while simultaneously removing a brake on leukemic cell cycling, would fit the clinical observation that low LAIR1 predicts worse survival. Disentangling these cell-intrinsic and microenvironmental contributions will be an important task for future studies.

The authors are careful to frame their conclusions appropriately, describing the work as offering a novel reference for the effect of LAIR1 in CLL rather than as an immediate therapeutic blueprint. The study was supported by the Jurong City Social Development Science and Technology Planning Project under grant number ZA42203, and the authors declared no competing interests. Published open access on 1 September 2026 in Annals of Hematology, the paper arrives at a moment when the field is actively searching for biomarkers that can refine risk stratification beyond the existing clinical and genetic markers, such as immunoglobulin heavy chain variable region mutation status and cytogenetic abnormalities. If LAIR1 expression can be validated as a prognostic marker in larger, independent cohorts, it could eventually help clinicians identify which patients need earlier intervention. And if the functional findings hold up, pharmacological strategies aimed at restoring or mimicking LAIR1 signaling might one day complement BTK and BCL-2 inhibition, attacking the disease from yet another angle. For now, the study stands as a reminder that some of the most informative clues about cancer biology come from molecules that were hiding in plain sight on the surface of the immune system’s own cells.

Subject of Research: The role of the LAIR1 immune receptor in regulating cell cycle progression and apoptosis in chronic lymphocytic leukemia

Article Title: LAIR1 regulated the development of chronic lymphocytic leukemia by modulating cell cycle and apoptosis

Article References: Min, M., Zhang, J., Wang, J., Chen, Y., & Luan, H. (2026). LAIR1 regulated the development of chronic lymphocytic leukemia by modulating cell cycle and apoptosis. Annals of Hematology. https://doi.org/10.1007/s00277-026-07263-y

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07263-y

Keywords: chronic lymphocytic leukemia, LAIR1, cell cycle, apoptosis, single-cell RNA sequencing, macrophages, tumor microenvironment, flow cytometry, Kaplan-Meier survival analysis, RT-qPCR, Western blot, hematology

This comprehensive retrospective cohort study analyzed 1,364 women carrying these BRCA1 founder variants, contextualizing their risk profiles against a vast control group of 11,350 breast cancer patients without known BRCA1 mutations. By integrating over a decade of follow-up data, the researchers deployed advanced statistical methodologies, including Kaplan-Meier survival analyses and Cox proportional hazards models, to elucidate nuanced risk differentials. The results vividly illustrated that BRCA1 mutation carriers face substantially elevated risks of secondary cancers compared to non-carriers.

One of the most striking findings was the substantial disparity in 10-year cumulative CBC risk between carriers of the two founder variants. Women harboring the c.5266dup mutation exhibited a 25.0% risk of developing contralateral breast cancer within ten years of initial diagnosis—a risk markedly higher than the 13.1% risk observed in c.4035del carriers. In stark contrast, the control population demonstrated only a 3.3% risk, underscoring the profound influence of BRCA1 mutations in shaping breast cancer recurrence. This disparity between c.5266dup and c.4035del underscores the necessity of variant-specific counseling.

Conversely, the OC risk profile displayed an inverse pattern. Women with the c.4035del BRCA1 variant manifested a dramatically heightened 10-year cumulative risk of 22.1% for ovarian cancer, compared to 13.0% among c.5266dup carriers. Both groups far exceeded the control cohort’s baseline OC risk of 1.0%. These differential risks emphasize that not all BRCA1 mutations confer uniform predispositions across cancer types, suggesting variant-specific pathogenic mechanisms at play, potentially involving tissue-specific DNA repair disruptions.

Age at PBC diagnosis emerged as a pivotal factor modulating CBC risk but had negligible impact on OC risk. Specifically, women younger than 40 years at primary breast cancer diagnosis exhibited more than double the risk (hazard ratio of 2.06) of contralateral breast cancer compared to older counterparts. This age effect did not translate to ovarian cancer risk, which remained largely unaffected by age at initial diagnosis. These observations point toward age-dependent biological influences or hormonal environments accelerating breast tissue vulnerability in mutation carriers.

Underlying the differences in CBC and OC risk between the BRCA1 variants could be structural or functional distinctions in the encoded proteins. The c.5266dup mutation, known to truncate BRCA1 protein prematurely, may differentially impair pathways integral to breast epithelial cell genomic stability. Meanwhile, the c.4035del mutation might impact regions of the protein more critical in ovarian tissue tumor suppression. Future molecular dissection will be paramount to validate these hypotheses and uncover mechanistic bases.

Importantly, this differentiation in risk profiles has direct and immediate clinical ramifications. Tailored surveillance strategies can now be devised for BRCA1 carriers based on their specific founder variant. Patients with c.5266dup may benefit from intensified breast cancer monitoring and consideration of contralateral mastectomy, especially if diagnosed before age 40. Conversely, c.4035del carriers might prioritize ovarian cancer risk reduction interventions, such as prophylactic salpingo-oophorectomy, given their pronounced OC predisposition.

The study also highlights the critical necessity of integrating comprehensive genetic testing into standard oncology workflows, reinforcing that a one-size-fits-all approach to BRCA1 mutation carriers may be suboptimal. Precision medicine efforts must factor in not only mutation presence but also particular variant characteristics to refine risk stratification and personalize therapeutic pathways. Such nuance is vital to improving long-term survival outcomes and quality of life.

From a public health perspective, these findings elevate the urgency of identifying founder variant carriers in populations with high BRCA1 mutation prevalence. Genetic counseling programs should incorporate these findings to educate patients about variant-specific risks and available preventive measures, fostering informed decision-making. Furthermore, these data advocate for enhanced genetic literacy among clinicians managing breast and ovarian cancers.

The implications for ongoing BRCA1-related research are profound. By delineating variant-specific phenotypes, this study paves the way for future trials assessing differential responses to targeted therapies such as PARP inhibitors. It also prompts exploration into genotype-driven resistance mechanisms. The molecular heterogeneity illuminated here will undoubtedly shape the future design of clinical trials and therapeutic algorithms.

In summary, the work presents compelling evidence that among BRCA1 mutation carriers, risk trajectories for secondary breast and ovarian cancers diverge strikingly depending on the specific founder variant. The c.5266dup variant confers a predilection for contralateral breast malignancies, markedly exacerbated by younger age at first cancer, while the c.4035del variant predisposes more heavily toward ovarian cancer risk. These insights empower clinicians and patients alike with refined prognostic information, catalyzing a paradigm shift toward more individualized, variant-centered cancer risk management strategies.

As genomic technologies and bioinformatic tools continue to evolve, the nuanced understanding of mutation-specific cancer risks, as illustrated by this research, epitomizes the future of oncogenetics. Personalized medicine thus not only strives for tailored treatments but also revolutionizes preventive care, enabling mutation carriers to navigate their cancer journeys with precise, informed guidance. This pioneering study reaffirms the vital role of precision oncology in saving lives and underscores the complexity underlying hereditary cancer syndromes.

Such revelations emphasize the dynamic and rapidly advancing landscape of cancer genetics. With more data emerging on specific variant effects, healthcare systems must adapt swiftly to translate these discoveries into clinical practice. Collaborative efforts among geneticists, oncologists, and patient advocates will be paramount to ensure that these scientific breakthroughs yield maximal real-world benefits, transforming hereditary cancer management worldwide.

Taken together, this research elevates our comprehension of BRCA1-associated cancer risks to unprecedented granularity. It illustrates vividly how founder variants within a single gene can orchestrate distinct oncogenic outcomes, reinforcing the intricate interplay between genetics and cancer biology. As the scientific community assimilates these findings, the path forward involves integrating variant-specific risk modeling into standard care, enabling earlier interventions and improved survival for women worldwide facing these formidable hereditary cancer risks.

Subject of Research: The study investigates the differing risks of contralateral breast cancer and ovarian cancer in female carriers of two BRCA1 founder gene variants (c.5266dup and c.4035del) following a primary breast cancer diagnosis.

Article Title: The difference in contralateral breast cancer and ovarian cancer risks for BRCA1 founder variant (c.5266dup, c.4035del) carriers with primary breast cancer

Article References: Loza, P., Irmejs, A., Daneberga, Z. et al. The difference in contralateral breast cancer and ovarian cancer risks for BRCA1 founder variant (c.5266dup, c.4035del) carriers with primary breast cancer. BMC Cancer 25, 1769 (2025). https://doi.org/10.1186/s12885-025-15110-y

Image Credits: Scienmag.com

DOI: 14 November 2025